Although the extent of remuscularization and its contribution to the restoration of function are unclear, these outcomes are likely strongly influenced by factors in the infarcted and/or ischemic environment. As an initial step toward understanding how the ischemic environment of host myocardium affects transplanted pluripotent cells, we have taken a reductionist approach wherein mESCs are cultured in medium containing ischemic myocardial interstitial fluid (iMIF). iMIF is generated in canine myocardium during eight hourly episodes of transient ischemia and collected on a daily basis, over a 24-day collection period. iMIF strongly reduced the numbers of pluripotent mESCs after 11 days in culture. This inhibitory effect, which was most pronounced for iMIF pools from early time points of the 24-day collection period, resulted from an inhibition of cell proliferation. iMIF also inhibited the differentiation of pluripotent mESCs into cardiomyocytes. By contrast, the expression of vascular smooth muscle and endothelial cell markers was relatively unaffected, consistent with previous findings that iMIF promotes angiogenesis. Taken together, these results suggest that whereas the ischemic/ infarcted environment is favorable to stem cell-mediated angiogenesis, it is hostile to cardiac myogenesis. These findings also imply that observations of mESC-mediated improvement of cardiac function after transplantation of pluripotent cells do not reflect remuscularization. pluripotent mouse embryonic stem cells; vascular smooth muscle; endothelial cells CELL THERAPY, using pluripotent embryonic stem cells (ESCs) or differentiated cells derived from them, constitutes an attractive choice for transplantation designed to regenerate defective organs. The treatment of cardiac disease constitutes a major target for cellular therapy. Obstacles preventing the use of pluripotent stem cells for this purpose have included ethical concerns, immunologic rejection, tissue-appropriate in vivo differentiation, and tumorigenicity. Although recent discoveries indicating that pluripotent cells (i.e., iPCs) can be induced from adult skin cells (32, 38) have diminished ethical and immunologic concerns, issues related to the behavior of transplanted stem cells following transplantation into ischemic/ infarcted myocardium remain unresolved. Among these issues, the questions of whether the ischemic/infarcted environment affects stem cell proliferation and differentiation into cardiovascular lineages, and/or promotion of tumorigenicity, must be clearly understood.
Although the extent of remuscularization and its contribution to the restoration of function are unclear, these outcomes are likely strongly influenced by factors in the infarcted and/or ischemic environment. As an initial step toward understanding how the ischemic environment of host myocardium affects transplanted pluripotent cells, we have taken a reductionist approach wherein mESCs are cultured in medium containing ischemic myocardial interstitial fluid (iMIF). iMIF is generated in canine myocardium during eight hourly episodes of transient ischemia and collected on a daily basis, over a 24-day collection period. iMIF strongly reduced the numbers of pluripotent mESCs after 11 days in culture. This inhibitory effect, which was most pronounced for iMIF pools from early time points of the 24-day collection period, resulted from an inhibition of cell proliferation. iMIF also inhibited the differentiation of pluripotent mESCs into cardiomyocytes. By contrast, the expression of vascular smooth muscle and endothelial cell markers was relatively unaffected, consistent with previous findings that iMIF promotes angiogenesis. Taken together, these results suggest that whereas the ischemic/ infarcted environment is favorable to stem cell-mediated angiogenesis, it is hostile to cardiac myogenesis. These findings also imply that observations of mESC-mediated improvement of cardiac function after transplantation of pluripotent cells do not reflect remuscularization. pluripotent mouse embryonic stem cells; vascular smooth muscle; endothelial cells CELL THERAPY, using pluripotent embryonic stem cells (ESCs) or differentiated cells derived from them, constitutes an attractive choice for transplantation designed to regenerate defective organs. The treatment of cardiac disease constitutes a major target for cellular therapy. Obstacles preventing the use of pluripotent stem cells for this purpose have included ethical concerns, immunologic rejection, tissue-appropriate in vivo differentiation, and tumorigenicity. Although recent discoveries indicating that pluripotent cells (i.e., iPCs) can be induced from adult skin cells (32, 38) have diminished ethical and immunologic concerns, issues related to the behavior of transplanted stem cells following transplantation into ischemic/ infarcted myocardium remain unresolved. Among these issues, the questions of whether the ischemic/infarcted environment affects stem cell proliferation and differentiation into cardiovascular lineages, and/or promotion of tumorigenicity, must be clearly understood.
Within sites of ischemia/infarction, factors from inflammatory and dying myocardial cells combine to create a complex biochemical environment in which transplanted cells must survive, migrate, and differentiate. Implications for stem cell transplantation have been reviewed (35) . After transplantation into infarcted myocardium, although pluripotent ESCs have been observed to differentiate into vascular cells and cardiomyocytes, the extent of histological engraftment, especially of cardiomyocytes, is extremely limited (4, 17-19, 24, 30) . The absence of significant engraftment is inconsistent with high levels of functional (i.e., echocardiographic) recovery (4, 18 -19, 31) observed following the transplantation of pluripotent cells into the infarcted myocardium. Hence, although the infarcted environment appears to be able to support the differentiation of transplanted pluripotent cells, the efficiency of this process, as well as the extent of proliferation and survival of the transplanted cells, is questionable.
A goal of this laboratory is to determine whether the transplantation of pluripotent cells, or their derivatives at various stages of the cardiomyogenic lineage, confers optimal engraftment and remuscularization after infarction. Optimal engraftment requires the identification of a temporal transplantation window that avoids the negative effects of inflammatory cytokines, before the onset of collagen deposition and remodeling. Such a window must be empirically determined by transplanting stem cells at selected intervals following infarction and monitoring histological outcomes. As a first step, we have used a model wherein the effects of ischemic myocardial interstitial fluid (iMIF), harvested from myocardium during a 24-day period of transient ischemia, can be evaluated on the in vitro behavior of pluripotent stem cells. Previous work has shown that iMIF induces an angiogenic response, inducing the proliferation of vascular smooth muscle and endothelial cell lines (22, 23, 36) . However, the effects of iMIF on pluripotent stem cells have not been assessed. We report that iMIF strongly reduced the numbers of murine embryonic stem cells (mESCs) during 11 days in culture, due to the inhibition of embryonic stem cell (ESC) proliferation. Also, iMIF significantly inhibited the differentiation of cardiomyocyte markers, but not of vascular smooth muscle or endothelial cell markers. These findings support the notion that improved cardiac function after mESC transplantation into infarcted tissue is likely mediated by angiogenic and/or paracrine mechanisms (14) rather than an engraftment and remuscularization of infarcted tissue. These data also indicate the need to define temporal windows and optimal cell types for stem cell transplantation. (2) . MIF was isolated from canine adult heart, exactly as previously described (33) . Briefly, a pneumatic occluder was placed around the left anterior descending coronary artery of an anesthetized dog, with a Doppler flow-probe inserted distally. A miniature multiport (inner diameter, 0.04 mm; and outer diameter, 0.8 mm) catheter was threaded into the myocardial wall of the left ventricle such that a ϳ2-cm segment of catheter containing 48 -0.5-mm-diameter holes was positioned within the area supplied by the left anterior descending coronary artery. Following a 7-day recovery period, ischemia was induced on a daily basis by activating the occluder for 2 min once every hour for 8 consecutive hours, followed by a collection of MIF. iMIF was collected over 24 consecutive days by injecting 4 ml lactated Ringer solution into the catheter while simultaneously harvesting 4 ml MIF from the effluent end. It is estimated that this procedure causes a 20-fold dilution of the iMIF as calculated from the catheter volume (22) . A control sham-operated dog that was identically instrumented was not occluded; sham-operated MIF (sMIF) was collected in parallel with iMIF. MIFs were collected on ice, filtered to remove cells and debris, aliquotted, and stored at Ϫ80°C. Each iMIF and sMIF preparation used in this study was obtained from a single dog; in this context it is noted that previous work has shown that MIF biological activity is very consistent between dogs (36) .
MATERIALS AND METHODS

Myocardial
ESC culture. A line of mESCs termed JϫL1 ES cells was derived from a cross of 129 ϫ 1/SvJ ϫ 129S1/SvlMJ mice. For expansion, mESCs were maintained in DMEM with pretested 10% fetal bovine serum (FBS, No. SH30071.03, Hyclone), 2 mM L-glutamine, 0.1 mM amino acids, 1 mM pyruvate, 0.1 mM ␤-mercaptoethanol, and penstrep; except as otherwise indicated, all components were from Specialty Media. The pluripotency of mESCs was maintained by the inclusion of leukocyte inhibitor factor to 10 g/ml and by growth on a feeder layer of mitomycin C-treated mouse embryonic fibroblasts (MEFs) that adhered to culture dishes precoated with 0.1% gelatin. For each passage, the plating densities of MEFs and mESCs were ϳ3 ϫ 10 4 and 10 4 cells/cm 2 , respectively. At no time were mESCs allowed to exceed 50% confluency.
All experiments were performed using mESCs at a low-passage number (Ͻ10). Experiments to evaluate the effects of iMIF were performed using pluripotent mESCs plated in monolayer. Briefly, mESCs were treated with collagenase IV (1 mg/ml) for 5 min, mechanically dissociated by gentle trituration, and preplated on bare cell culture dishes for 30 min to remove MEFs. mESCs were counted and replated on gelatin-coated culture dishes without MEFs at a density of 5 ϫ 10 5 cells/cm 2 in defined medium consisting of RPMI medium 1640 (No. 22400-097, Invitrogen) containing 25 mM HEPES buffer and L-glutamine, supplemented with 2% B-27 (No. 17504-044, Invitrogen). B-27 is a proprietary-defined serum substitute containing vitamin A, insulin, transferrin, and selenium (8) .
To evaluate the effects of MIF, experiments were performed using RPMI/B27 supplemented with 10% (vol/vol) iMIF or 10% sMIF as a control. These levels were selected based on previous work evaluating the effect of MIF on vascular cell lines (36) . To best simulate the in vivo situation, as well as to adhere to the conditions used in the previous iMIF experiments (36) , sMIF was normalized to iMIF based on equivalent volume (10%) rather than on equivalent content of total protein; moreover, normalization based on protein content would have exhausted the supplies of sMIF due to its relatively low protein content. Medium with iMIF or sMIF was exchanged on a daily basis up to 11 days in vitro when the cells were harvested for immunohistochemical and RT/PCR determinations. In some experiments, FBS was replaced with cell culture medium containing 10% knockout serum replacement (KSR; No. 10828-028, Invitrogen), a proprietary formulation, or serum replacement 2 (SR2; No. S9388, Sigma), which contains BSA, transferrin, and insulin.
Immunohistochemistry. Cultures under each experimental condition were immunostained for the expression of the differentiation marker sarcomeric ␣-myosin heavy chain (␣-MHC) using monoclonal antibody MF20 (Developmental Studies Hybridoma Bank) and the M-phase proliferation marker phosphorylated histone H3 using polyclonal antibody phosphorylated histone H3 (H3P; No. 06-570, Millipore). Cells were fixed with methanol at Ϫ20°C (2 h), followed by rehydration in decreasing methanol/water series. The cells were blocked using serum-free protein block (No. X0909, Dako) for 30 min at 4°C, followed by an application of primary antibody, MF20 diluted 1:60 or H3P diluted 1:600, in antibody diluent (Dako S0809) overnight at 4°C. After a wash, secondary antibody (Alexa fluor 594 donkey anti-mouse for MF20; Alexa fluor 488 donkey anti-rabbit for H3P) was applied using a 1:750 dilution in antibody diluent for 1 h at 4°C. Nuclei were counterstained with 4Ј,6-diamidino-2-phenylindole (DAPI; 500 ng/ml).
Estimation of cardiomyocyte differentiation. Because cardiomyocytes differentiate in randomly located multicellular clusters, the extent of cardiomyocyte differentiation in the cultures was assessed by determining the area occupied by MHC-positive cells. Approximately 20 ϫ100 images were photomicrographically captured in each culture well followed by two-dimensional quantitation of the fluorescent Alexa fluor 594 signal using ImageJ software. To ensure reproducibility, the images were photomicrographically captured at the same exposure settings. The images were opened in ImageJ, and a signal intensity threshold was established that was kept constant during image processing. Each image was converted into binary, with the threshold signal designated as black and the nonsignal as white. The positive-signal pixel area was compared with total pixel area. The area occupied by DAPI was similarly assessed.
Assessment of cell death. Cells fixed with methanol, as described in Immunohistochemistry, were stained using the APO-BrdU TUNEL Assay (No. A23210, Invitrogen). Nuclei were counterstained with DAPI (500 ng/ml) for 5 min. Eight random fields from each well were photomicrographed under ϫ100 magnification, capturing the paired DAPI and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) fluorescence channels. Each field was assessed for the numbers of TUNEL-positive nuclei by enumerating the TUNEL signals that overlaid the DAPI signals; the TUNEL signals that did not overlie a DAPI signal were excluded.
Radioactive semiquantitative RT-PCR. Cultures were lysed and RNA was purified using the Qiagen RNeasy Plus mini kit (No. 73134, Qiagen) according to the manufacturer's recommendations. For each sample, precisely 500 ng total RNA quantitated by A260 were reversetranscribed using iScript cDNA synthesis kit (No. 170-8891, Bio-Rad) per the manufacturer's recommendations. Radioactive PCR was performed on equal aliquots of RT template using GoTaq Green Master Mix (No. M7123, Promega) supplemented with 1 Ci 32 P-dATP per reaction. The following primer pairs were included in individual reaction mixtures at a final concentration of 0.5 g/ml: calponin-1, forward 5Ј-GTTGCGCTTGTCTGTGTCAT-3Ј, and reverse 5Ј-AGC-CAGGAGAGTGGACTGAA-3Ј; GAPDH, forward 5Ј-AACTTTG-GCATTGTGGAAGG-3Ј, and reverse 5Ј-ACATTGGGGGTAGGA-ACAC-3Ј; ␣-MHC, forward 5Ј-GAGATTTCTCCAACCCAG-3Ј, and reverse 5Ј-TCTCCTTCTCAGACTTCCGC-3Ј; smooth muscle MHC, forward 5Ј-CCTTTTCCGATGGATTCTCA-3Ј, and reverse 5Ј-GCT-TCTGAAATTTGGGGTGA-3Ј; Nkx2.5, forward 5Ј-CAAGTGCT-CTCCTGCTTCC-3Ј, and reverse 5Ј-GGCTTTGTCCAGCTCCACT-3Ј; P53, forward 5Ј-GTGTCCGCGCCATGGCCATCTACAAGA-3Ј, and reverse 5Ј-CTGGGGGCAGTTCAGGGCAAAGGACTTC; Tie-2, forward 5Ј-TGAAGGGCAAGATGGATAGG-3Ј, and reverse 5Ј-TTCGG-CATCAGACACAAGAG-3Ј; and Cdh5 (vascular endothelial cadherin), forward 5Ј-AGACACCCCCAACATGCTAC-3Ј, and reverse 5Ј-GCAAACTCTCCTTGGAGCAC-3Ј. PCR was performed using a 10-min hot start (94°C) followed by 35 cycles of 60 s melt (94°C), 45 s annealing (57°C), and 45 s elongation (72°C).
Statistical methods. All experimental conditions were performed in triplicate. Statistical significance was evaluated by using a two-tailed equal variance Student's t-test at the 95% confidence limit.
RESULTS
Factors in serum inhibit cardiomyogenesis. Experiments using mESCs are usually performed in medium supplemented with up to 15% FBS to support cellular survival, growth, and differentiation. However, because of the complexity and concentration of unknown proteins in FBS, proteins in MIF that may be present at relatively low levels may be overwhelmed by FBS components. Moreover, serum was recently shown to inhibit cardiomyogenesis in human ESCs (26) . Hence, it was important to establish the defined culture conditions that permit ESC growth and differentiation into cardiomyocytes to unambiguously observe the effects of MIF. In preliminary experiments we assessed the survival and differentiation of mESCs plated in monolayer culture, as well as in embryoid body (EB) culture, using medium supplemented with serum (1% or 10% FBS), KSR (10%), or SR2 (1ϫ). Neither 1% serum nor SR2 supported the survival or differentiation of mESCs cultured either in monolayer or as EBs (not shown). And, although the medium supplemented with KSR maintained the survival of mESCs grown under either format, no evidence of cardiomyogenic differentiation was observed (not shown). As anticipated, the medium supplemented with 10% FBS maintained mESCs cultured in both monolayer and as EBs.
We then investigated the alternative of using a defined medium consisting of RPMI/B27. As a positive control we supplemented RPMI/B27 with activin-A and bone morphogenic protein (BMP), factors that induce cardiomyogenesis in pluripotent human ESCs (20) . Figure 1 quantitatively depicts the cardiomyogenic areas in cultures detected by immunostaining sarcomeric MHC, after 11 days of growth under the following conditions: 1) RPMI/B27 supplemented with activin-A and BMP-4, 2) RPMI/B27 alone, 3) RPMI supplemented with 10% FBS for the first 5 days in vitro, and 4) RPMI supplemented with 10% FBS for the entire 11 days of the culture period. Relative to mESCs cultured in RPMI/B27 alone, the supplementation with activin-A and BMP-4 induced a 6.5-fold increase in the area of the culture dish comprised of MHC-positive cells. By contrast, the supplementation with 10% FBS for either the first 5 days or for the full 11 days of culture significantly reduced the extent of differentiation relative to ESCs grown in RPMI/B27 alone. These results indicate that FBS contains cardiomyogenic inhibitors. Hence, we decided to evaluate the proliferative and differentiative effects of iMIF using defined culture conditions that exclude FBS.
iMIF reduces ESC numbers. Results in Fig. 1 demonstrated that the defined medium (RPMI/B27) supported growth and cardiomyogenic differentiation in mESCs after 11 days in the monolayer culture. This provided an opportunity to address, in the absence of the ambiguity caused by serum factors, the effects of supplementing RPMI/B27 with iMIF on mESC growth and differentiation into cardiomyocytes. As previously described (36) , iMIF and sMIF samples were collected from canine myocardium for 24 days. On each day, iMIF was collected following an 8-h period during which ischemia was induced for 2 min every hour for 8 h. sMIF was collected in parallel from hearts that had been sham operated. For each experiment, pools representing 3 consecutive days of collection of iMIF or sMIF, termed "MIF collection pools," were used to supplement RPMI/B27 at a concentration of 10% vol/vol, the level of which was selected based on previous experiments evaluating the effects of iMIF on vascular cell lines (36) . Most experiments used the following MIF collection pools: days 1-3, 7-9, 13-15, and 22-24 . The selection of these pools was based on findings from previous studies (22, 23, 36) .
First, the effects of MIF were monitored for morphological change in mESCs after 11 days in culture. As shown at low magnification ( Fig. 2A) , ESCs treated with all collection pools of iMIF exhibited reduced cellular density, by contrast with sMIF or medium alone (not shown). To quantitate this finding, the density of nuclei (i.e., cells) in each DAPI-stained dish was estimated by processing ϫ40 images using ImageJ analysis. As shown in Fig. 2B , after 11 days in culture, mESCs grown in all iMIF collection pools exhibited a reduced cell culture density, with the most striking reductions caused by iMIF pools 1-3 and 7-9. By contrast, sMIF did not reduce mESC density, with the exception of cultures that were treated with the earliest collection pool (sMIF, pool 1-3) . The convention of using ImageJ analysis to estimate cell numbers was employed to enable multiple determinations on each culture, thereby conserving MIF, which is in extremely limited supply. Because ImageJ estimates density in only two dimensions, the cell numbers were likely underestimated because random areas of ESCs become multilayered during the 11-day cell culture period. To verify the estimates of the cell number provided by ImageJ quantitation, ESCs were exposed to MIFs from an Fig. 1 . Serum inhibits cardiomyogenesis in cultured embryonic stem cells (ESCs). Murine ESCs were induced to differentiate in monolayer culture by growing for 11 days in either 1) RPMI/B27 supplemented with 100 ng/ml activin-A for 1 day followed by RPMI/B27 containing 10 ng/ml bone morphogenic protein-4 (BMP-4) for 4 days, then RPMI/B27 only for 6 days; 2) RPMI/B27 alone for 11 days; or 3) RPMI/B27 supplemented with 10% FBS for either the first 5 days or 4) for the full 11 days. All media were exchanged for fresh medium daily. Bars depict the extent of immunohistochemically detected expression of sarcomeric myosin heavy chain (MHC), detected using monoclonal antibody MF20 followed by ImageJ quantitation. The extent of MHC expression denoted by each bar is shown relative to cells grown in RPMI/B27 only, which was set at 1.0. Error bars represent means Ϯ SE; numbers in parentheses indicate the number of cultures that were evaluated. Statistical significance was assessed by Student's t-test. *P Ͻ 0.05, presence of 10% FBS for the 1st 5 days and full 11 days of the culture period compared with cells grown in RPMI/B27 only. alternative early stage collection pool (days 4 -6; this convention was used to conserve MIF). The cells were trypsinized and directly counted with a hemocytometer. As anticipated, this revealed dramatically reduced numbers of mESCs in cultures treated with early stage MIFs (Fig. 2C) .
iMIF inhibits ESC proliferation. Findings shown in Fig. 2 indicated that iMIF reduced mESC numbers by 11 days in culture, especially in cultures treated with early collection pools. Reductions in cell number can result from processes induced by iMIF, including the inhibition of cell proliferation and/or increased levels of apoptosis. To assess the relative contribution of these processes toward the results shown in Fig.  2 , the determinations shown in Fig. 3 were performed. To assess whether the reduced cell numbers reflected iMIF-induced inhibition of mESC proliferation, mESCs were immunostained using an antibody that detects H3P, a marker of mitotic prophase. As shown in Fig. 3A , the results were highly consistent with Fig. 2 , revealing up to a 50% inhibition by all iMIF collection pools, whereas only the earliest collection pool of sMIF was inhibitory. To assess whether cell death contributed to reduced mESC numbers, TUNEL assays were performed during the second day of the culture period, using an alternative collection pool (days 4 -6, to conserve MIF supplies); this early stage of the cell culture period was selected for analysis because of the likelihood that dying cells were removed from the cultures by day 11. As shown in Fig. 3B , neither iMIF nor sMIF caused an increase in cell death during the second day of the culture period; TUNEL determinations performed after 11 days of treatment with iMIF and sMIF revealed similar results (not shown). Moreover, H3P immunostaining in ESCs treated with early iMIF for only 2 days revealed a cell cycle inhibition similar to that observed after 11 days in culture (Fig. 3B, left) . The results in Fig. 3 indicate that cell cycle inhibition was the most likely cause of the reduced numbers of mESCs shown in Fig. 2 .
iMIF inhibits cardiomyocyte differentiation in mESCs. A variety of reports have indicated that pluripotent cells can differentiate into cardiomyocytes, albeit inefficiently, after transplantation into infarcted myocardium (4, 17-19, 24, 30) . Therefore, it was of interest to assess whether iMIF induces mESC differentiation into cardiomyocytes. As shown in Fig. 4A , based on percentages of culture dish area occupied by sarcomeric MHC-positive cells, all iMIF collection pools strongly inhibited cardiomyogenic differentiation (average, ϳ85%) compared with the extent of cardiomyogenic differentiation in control medium. Curiously, data in Fig. 4 also revealed that all sMIF collection pools inhibited MHC differentiation, according to a trend wherein the latest collection pool was the least inhibitory and the earliest collection pool was the most inhibitory; while the latter is suggestive of catheter-induced injury (also noted in Figs. 2 and 3) , the finding in this instance that the later collection pools of sMIF significantly inhibited cardiomyogenesis suggests that this may be a normal property of the myocardial environment (see DISCUSSION) . The finding that iMIF strongly inhibited cardiomyogenesis was corroborated by semiquantitative RT-PCR determinations (Fig. 4C) , which re- Fig. 2 . Ischemic myocardial interstitial fluid (iMIF) reduces ESC culture density. Murine ESCs were cultured for 11 days as described in MATERIALS AND METHODS, using defined medium supplemented with 10% (vol/vol) iMIF or sham-operated MIF (sMIF) that was harvested from canine myocardium and pooled from the indicated collection days. Medium, including MIFs, were changed daily. A: phase-contrast microscopy performed on the 11th day of the culture period. B: quantitatively depiction of the effect of MIFs on cell density in the cultures, as determined by 4Ј,6-diamidino-2-phenylindole (DAPI) staining. Randomly selected areas of each culture were photographed under ϫ40 magnification, and areas occupied by DAPI staining were quantitated via ImageJ analysis. *P Ͻ 0.01 and **P Ͻ 0.02 compared with RPMI/B27 control group; ϩP Ͻ 0.05 compared with sMIF collected from same days. C: hemocytometer counts of trypsinized ESCs cultured for 11 days in the presence of pooled iMIF and sMIF using an alternative early stage collection pool (days 4 -6). *P Ͻ 0.05 compared with RPMI/B27 control group; ϩP Ͻ 0.05 compared with sMIF. In B and C, the error bars depict means Ϯ SE, and numbers in parentheses indicate the number of cultures evaluated. Statistical significance was assessed by Student's t-test.
vealed that the first three collection pools of iMIF strongly inhibited the expression of cardiomyogenic markers ␣-MHC and Nkx-2.5. Although sMIF collection pool 1-3 strongly inhibited the differentiation of these markers (as predicted from Fig. 4A ), the marker expression in cells exposed to all three later sMIF pools was unaffected or perhaps increased.
Previous work demonstrated that the proliferation of vascular cell lines was promoted by iMIF (22, 23, 36) and that mESCs differentiated into vascular cells within an infarcted myocardial environment (30) . These findings, vis-à-vis the results in Fig. 4 indicating that iMIF strongly inhibited the differentiation of mESCs into cardiomyocytes, prompted assessments of whether iMIF affected the expression of vascular cell markers in pluripotent mESCs after 11 days in vitro. In contradistinction to the strong inhibitory effects of iMIF on the expression of cardiomyocyte markers (Fig. 4) , RT-PCR revealed that the expression of neither the vascular endothelial cell markers vascular endothelial cadherin and Tie-2 nor the smooth muscle cell marker calponin-1 was affected by any collection pool of iMIF or sMIF (Fig. 5) .
DISCUSSION
This study was performed to assess the effects of factors in interstitial fluid isolated from transiently ischemic myocardium (iMIF) on the proliferation and differentiation of pluripotent ESCs. To assess the effects of iMIF, we designed an in vitro experimental model wherein mESCs were cultured under defined conditions that permit growth and differentiation into cardiomyocytes, in the absence of confounding and anticardiomyogenic effects due to FBS. The results indicated that iMIF, when applied as a 10% vol/vol supplement to cultured ESCs for 11 days, strongly reduced cell numbers, an effect mediated by cell cycle inhibition but apparently not increased apoptosis as respectively revealed by phosphohistone H3 and TUNEL immunolabeling. In general, MIF pools from the early phases of the 24-day transient ischemic period had more antiproliferative activity than MIF collected during later phases, suggesting that the ischemic protocol may induce preconditioning factors (15) in later-stage MIF pools. This was accompanied by strong inhibition of cardiomyocyte differentiation that was caused by all the collection pools, as indicated by immunostaining and the absence of the expression of cardiomyocyte-specific markers. The early collection pools of sMIF (days 1-3) mimicked iMIF, suggesting that surgical instrumentation (as in this instance), as well as other myocardial injuries, causes the release of anticellular factors. However, the differentiation of ESCs into vascular cells was relatively unaffected at all collection days.
It is informative to compare these findings with several recently published studies indicating that transplantation of pluripotent mESCs improves cardiac function after myocardial infarction (4, 17-19, 24, 30, 31) . All these investigations reported the essentially common finding that, based on echocardiography, the transplantation of ESCs was followed by remarkably improved cardiac function, to between 45 and 100% of normal levels. The mechanism of this phenomenon, which likely includes ESC-mediated paracrine signaling (14), remains poorly understood. Although some transplanted ESCs apparently differentiated into cardiomyocytes (4, 17-19, 24, 30) , their sporadic occurrence, plus the low efficiency of histological engraftment, was insufficient to explain the remarkably high extent of functional recovery, which ranged from 45 to 100% of preinfarction levels. These observations, which predict that factors in the ischemic myocardial environment (i.e., iMIF) inhibit expansion and differentiation of ESCs into cardiomyocytes, are consistent with the in vitro results reported here. Taken together, these findings suggest that to remuscularize injured myocardium, the following requirements must be met. First, an optimal window of opportunity for cell transplantation must be defined, between the peak of inflammation and the onset of scar tissue formation; in this regard the strong reduction of mESC numbers caused by MIF collection pools 1-9 ( Fig. 2) indicates that early transplantation windows should be avoided. Second, transplanted cells should be suspended in vehicle containing antiapoptotic (despite the finding in Fig. 3B ) and anti-inflammatory agents; the use of such a vehicle was recently shown to improve the engraftment of stem cell-derived cardiomyocytes (20) . Third, to thwart the antiproliferative/antidifferentiative myocardial environment predicted by these studies, large numbers of cells that are predifferenti- ated into the cardiomyogenic lineage should be transplanted. Although the findings in Figs. 2 and 3 indicate that the ischemic myocardial environment would not support tumor formation (discussed below), the use of predifferentiated cells nonetheless minimizes this possibility while obviating the requirement of pluripotent cells to properly differentiate after transplantation.
The antiproliferative effect of iMIF is seemingly inconsistent with observations of teratoma formation after transplanting infarcted hearts with pluripotent mouse (4, 24, 25, 31) or human (9, 21) ESCs. However, teratoma formation has been a relatively infrequent observation (17, 30) , and tumors may be caused by transplanting inappropriately high numbers of stem cells (5) . We previously speculated that tumors may result from the inadvertent injection of ESCs into nonmyocardial sites, for example into the pericardial cavity (24) . Regarding this issue, it may be relevant that Prokhorova et al. (27) recently reported that teratoma formation by human ESCs depends on the tissue environment; although tumor formation consequent to intracardiac injection was not addressed in their study, it is noteworthy that the skeletal muscle environment supported the least incidence of teratoma formation.
sMIF shared some of the inhibitory effects of iMIF, which was surprising because the composition of iMIF is significantly more complex than sMIF (22) . For example, the earliest collection pool of sMIF inhibited the expansion (Fig. 2 ) and mitotic index (Fig. 3A) of cultured ESCs. Because this effect on cell proliferation was only caused by the earliest sMIF collection pool, it is speculated that this represents an artifact caused by myocardial injury during catheter implantation, rather than transient ischemia. In this context it is interesting to consider that the combined factors released during myocardial instrumentation injury and transient ischemia may comprise early pools of iMIF, mimicking the permanently infarcted environment that was used in all the animal studies discussed above (4, 17-19, 24, 30, 31) . Hence, it would follow that transplantation should be avoided during periods immediately after myocardial injury. In addition, all sMIF collection pools inhibited differentiation of MHC-positive cardiomyocytes (Fig. 4A) , despite the expression of cardiomyogenic mRNAs in cells treated with later sMIF collection pools (Fig. 4C) . Considered together, the findings in Fig. 4 suggest the possibility that whereas the earliest collection pool of sMIF (i.e., pools 1-3) inhibits the specification of the cardiomyogenic lineage, later collection pools (pools 7-9, 13-15, and 22-24) , while allowing entry to the cardiomyogenic lineage as indicated by mRNA expression (Fig. 4C) , inhibit translation into cardiomyocyte protein (Fig. 4A) ; this interpretation is in accord with previous findings that the differentiation of sarcomeric proteins in muscle cells is posttranscriptionally regulated (29, 34) . These data further suggest that contrary to the ability of the embryonic myocardial environment to support cardiomyogenesis (4, 12, 13, 28) , the adult myocardial environment is not conducive to cardiomyocyte differentiation. This provides additional support for the notion that remuscularization of damaged myocardium may require the use of cells that are already committed to the cardiomyogenic lineage. However, while the use of cardiomyogenic cells positioned early in the lineage would conceivably facilitate their ability to integrate with existing healthy myocardium as they become terminally differentiated, such a strategy may have to consider the possibility that factors in healthy myocardium may retard their terminal differentiation.
Contrary to the results on ESCs reported here, previous work indicated that all iMIF collection pools increased the proliferation of adult angiogenic cells, per experiments performed on vascular smooth muscle cell and endothelial cell lines (36) . These findings are consistent with later reports showing that ischemic episodes induce a transient increase in capillary density, concomitant with a sustained increase in blood flow within the canine myocardium (23) . These proangiogenic effects of iMIF are consistent with findings that among more than 200 proteins present in iMIF (22) , three that have been characterized-VEGF and angiopoietin-2 (23) as well as haptoglobin (22)-promote angiogenesis, with the former promoting cell growth and the latter promoting vascular morphogenesis. These results indicate that iMIF has angiogenic activity. It will be interesting to assess whether these and/or yet uncharacterized factors in iMIF are anticardiomyogenic. Although VEGF was shown to improve cardiac function in infarcted hearts when used as adjuvant with transplanted ESCs (37), this likely reflects its proangiogenic activity rather than a procardiomyogenic effect (18, 19) ; on the other hand, VEGF has been shown to promote cardiomyogenesis in ESCs (11) . Regarding the uncharacterized factors in iMIF, it will be interesting to determine whether the mitotic inhibitors transforming growth factor-␤ and TNF-␣ are present, since levels of these acute-phase proteins are increased in ischemic myocardium (7, 10, 16) . These proteins are of particular interest because it has been shown that transforming growth factor-␤ is procardiomyogenic to transplanted pluripotent ESCs (4, 18, 19) . And, TNF-␣ has been shown to inhibit the proliferation of bone marrow-derived adult stem cells (39) , c-kit-positive derivatives which are attractive candidates to restore infarcted myocardium from within (3), as well as to promote cardiomyogenic differentiation of pluripotent ESCs in the myocardium (7) .
In summary, we have shown that factors in chronically ischemic myocardium inhibit cardiac myocyte differentiation and decrease proliferation in cultured pluripotent mESCs. It is noteworthy that factors produced during only 24 days of chronic ischemia were evaluated in this study. It will be interesting to extend the MIF collection period to examine the possibility that iMIF produced during early ischemia (i.e., days 1-24) supports angiogenesis (36), followed after day 24 by the production of iMIF that supports cardiomyogenesis; in other words, angiogenesis occurring during the early periods of ischemia (23) may condition the myocardium to support cardiomyogenic cells which are transplanted at a later time point. In addition, this study evaluated iMIF produced in chronically ischemic myocardium. It will therefore be of interest to assess the effect of iMIF produced by infarcted myocardium, which is predicted, in accord with the interpretation of the findings presented here, to have similar or perhaps exacerbated effects on pluripotent ESCs.
